Article
Clinical significance of elevated chemokine CCL5 in aneurysmal subarachnoid haemorrhage (aSAH)
Klinische Bedeutung von erhöhtem Chemokin CCL5 bei aneurysmatischer Subarachnoidalblutung (aSAH)
Search Medline for
Authors
-
Sajjad Muhammad
- University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Universitätsklinikum Bonn, Neurosurgery, Bonn, Deutschland
-
Thomas M. Kinfe
- Universitätsklinikum Bonn, Neurochirurgie, Bonn, Deutschland
-
Alf Lamprecht
- Universität Bonn, Pharmazeutisches Institut, Bonn, Deutschland
-
Shafqat Rasul Chaudhry
- Universitätsklinikum Bonn, Neurosurgery, Bonn, Deutschland; University of Bonn, Department of Pharmaceutics, Bonn, Deutschland
| Published: | May 8, 2019 |
|---|
Outline
Text
Objective: Aneurysmal subarachnoid hemorrhage (aSAH) has the worst consequences of all stroke subtypes. Accumulating evidence suggests a critical role of inflammation in aSAH and post-aSAH complications. Chemokines play an important role in inflammation via leucocyte chemotaxis. The current study aims to investigate the role of systemic CCL5/RANTES after aSAH. The secondary aim was to determine associations between different post-aSAH complications and clinical outcome with systemic CCL5 levels.
Methods: We recruited 80 aSAH and 24 control patients prospectively. Peripheral venous blood was collected in serum gel tubes. The blood was centrifuged to harvest the serum, which was immediately frozen at −80 °C until analysis. Serum CCL5 levels were quantified using enzyme linked immunoassay. Patient records including age, gender, post-aSAH complications, aneurysm treatment, and clinical outcome (modified Rankin scale and Glasgow outcome scale) were retrieved from patient record file.
Results: Serum CCL5 levels were significantly elevated after aSAH on day 1 and day 7 in comparison to control patients. Classification of patients in good clinical outcome (mRS 0–2 or GOS 4–5) and poor clinical outcome (mRS 3–6 or GOS 1–3) showed that serum CCL5 levels were significantly higher in patients with good clinical outcome at discharge. Interestingly, CCL5 levels were significantly lower on day 7 in patients with intracerebral bleeding, chronic hydrocephalus and pneumonia. Serum CCL5 levels on day 7 showed a positive correlation with clinical outcome (mRS and GOS).
Conclusion: Serum CCL5 levels were elevated during early and delayed brain injury phases after aSAH. Serum CCL5 level on day 7 is independently associated with clinical outcome (mRS and GOS) at discharge.
